Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11193MR)

This product GTTS-WQ11193MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11193MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3324MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ802MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ12142MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ3898MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ3593MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ12639MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ5191MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ6592MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW